Nuveen Asset Management LLC Lowers Holdings in DaVita Inc. (NYSE:DVA)

Nuveen Asset Management LLC decreased its position in DaVita Inc. (NYSE:DVA - Free Report) by 28.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 131,548 shares of the company's stock after selling 51,902 shares during the quarter. Nuveen Asset Management LLC owned 0.16% of DaVita worth $19,673,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in DVA. SBI Securities Co. Ltd. bought a new stake in DaVita in the 4th quarter worth approximately $41,000. Coppell Advisory Solutions LLC increased its stake in DaVita by 50.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock worth $45,000 after acquiring an additional 100 shares during the last quarter. Canada Post Corp Registered Pension Plan bought a new stake in DaVita in the 4th quarter worth approximately $55,000. Venturi Wealth Management LLC increased its stake in DaVita by 59.8% in the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after acquiring an additional 152 shares during the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of DaVita by 39.7% in the 4th quarter. Blue Trust Inc. now owns 461 shares of the company's stock worth $76,000 after purchasing an additional 131 shares during the period. Institutional investors own 90.12% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on DVA shares. Truist Financial dropped their target price on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday, May 19th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Sanford C. Bernstein set a $184.00 target price on DaVita in a report on Friday, February 21st. Cowen reiterated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Barclays lifted their target price on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $164.50.

DaVita Trading Up 1.2%

DVA traded up $1.63 during trading hours on Tuesday, reaching $139.82. 794,960 shares of the company's stock traded hands, compared to its average volume of 826,146. The firm has a 50-day moving average price of $145.09 and a 200 day moving average price of $153.34. DaVita Inc. has a 52-week low of $131.76 and a 52-week high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The firm has a market capitalization of $10.56 billion, a PE ratio of 13.02, a PEG ratio of 1.07 and a beta of 1.14.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The business had revenue of $3.22 billion during the quarter, compared to analysts' expectations of $3.22 billion. During the same period in the prior year, the business earned $2.26 EPS. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. As a group, sell-side analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.